These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
311 related articles for article (PubMed ID: 17383932)
61. 'ACE inhibitors are better than AT(1) receptor blockers (ARBs)' - controversies in heart failure. White HL; Hall AS Eur J Heart Fail; 2000 Sep; 2(3):237-40. PubMed ID: 10938482 [No Abstract] [Full Text] [Related]
62. [Angiotensin converting enzyme inhibitors and angiotensin II type 1 receptor blockers]. Mogi M; Horiuchi M Nihon Rinsho; 2006 Oct; 64 Suppl 7():724-9. PubMed ID: 17461230 [No Abstract] [Full Text] [Related]
63. Angiotensin-converting enzyme inhibitor use and pneumonia risk in a general population. van de Garde EM; Souverein PC; van den Bosch JM; Deneer VH; Leufkens HG Eur Respir J; 2006 Jun; 27(6):1217-22. PubMed ID: 16455828 [TBL] [Abstract][Full Text] [Related]
64. Recommended Heart Failure Medications and Adverse Drug Reactions in Women. Bots SH; den Ruijter HM Circulation; 2019 Mar; 139(12):1469-1471. PubMed ID: 30883224 [No Abstract] [Full Text] [Related]
65. Use of angiotensin receptor blockers and the risk of cancer. Pasternak B; Svanström H; Callréus T; Melbye M; Hviid A Circulation; 2011 Apr; 123(16):1729-36. PubMed ID: 21482967 [TBL] [Abstract][Full Text] [Related]
66. The effectiveness of beta-blockers in women with congestive heart failure. Keyhan G; Chen SF; Pilote L J Gen Intern Med; 2007 Jul; 22(7):955-61. PubMed ID: 17468890 [TBL] [Abstract][Full Text] [Related]
67. Use of ACE inhibitors and ARBs in hypertensive women of childbearing age. Martin U; Foreman MA; Travis JC; Casson D; Coleman JJ J Clin Pharm Ther; 2008 Oct; 33(5):507-11. PubMed ID: 18834365 [TBL] [Abstract][Full Text] [Related]
68. [Effect of strict glycemic control on clinical state and course of the disease in patients with chronic heart failure and type II diabetes mellitus. Results of the REMBO "rational effective multicomponent therapy in the struggle against diabetes mellitus in patients with congestive heart failure" study]. Lapina IuV; Filatov DN; Mareev VIu; Narusov OIu; Bolotina MG; Shestakova MV; Masenko VP; Litonova GN; Baklanova NA; Belenkov IuN Kardiologiia; 2008; 48(9):17-27. PubMed ID: 18991816 [TBL] [Abstract][Full Text] [Related]
69. The effects of angiotensin-receptor blockers on mortality and morbidity in heart failure: a systematic review. Shibata MC; Tsuyuki RT; Wiebe N Int J Clin Pract; 2008 Sep; 62(9):1397-402. PubMed ID: 18793376 [TBL] [Abstract][Full Text] [Related]
70. Diabetic kidney disease: an ACEI (or an ARB) in the hole. Yee J Adv Chronic Kidney Dis; 2014 May; 21(3):251-5. PubMed ID: 24780451 [No Abstract] [Full Text] [Related]
71. Differential impact of NSAIDs on rate of adverse events that require hospitalization in high-risk and general veteran populations: a retrospective cohort study. Pratt N; Roughead EE; Ryan P; Gilbert AL Drugs Aging; 2010 Jan; 27(1):63-71. PubMed ID: 20030433 [TBL] [Abstract][Full Text] [Related]
72. Influence of gender of physicians and patients on guideline-recommended treatment of chronic heart failure in a cross-sectional study. Baumhäkel M; Müller U; Böhm M Eur J Heart Fail; 2009 Mar; 11(3):299-303. PubMed ID: 19158153 [TBL] [Abstract][Full Text] [Related]
73. Angiotensin-converting enzyme inhibition in congestive heart failure: benefit and perspective. Pfeffer MA Am Heart J; 1993 Sep; 126(3 Pt 2):789-93. PubMed ID: 8362754 [TBL] [Abstract][Full Text] [Related]
74. [The use of ACE inhibitors in treatment of chronic heart failure should still be emphasised]. Shi ZW Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Sep; 34(9):771-3. PubMed ID: 17217678 [No Abstract] [Full Text] [Related]
75. The CHARM programme. Cleland JG; Freemantle N Lancet; 2003 Nov; 362(9396):1679. PubMed ID: 14630460 [No Abstract] [Full Text] [Related]
76. The use of angiotensin-converting enzyme inhibitors in the treatment and prevention of congestive heart failure. Toher CA; Francis GS Coron Artery Dis; 1993 Jan; 4(1):37-43. PubMed ID: 8269182 [No Abstract] [Full Text] [Related]
77. Clinical features of and effects of angiotensin system antagonists on amiodarone-induced pulmonary toxicity. Nikaido A; Tada T; Nakamura K; Murakami M; Banba K; Nishii N; Fuke S; Nagase S; Sakuragi S; Morita H; Ohe T; Kusano KF Int J Cardiol; 2010 Apr; 140(3):328-35. PubMed ID: 19106010 [TBL] [Abstract][Full Text] [Related]
78. Aspirin does not adversely affect survival in patients with stable congestive heart failure treated with Angiotensin-converting enzyme inhibitors. Aumégeat V; Lamblin N; de Groote P; Mc Fadden EP; Millaire A; Bauters C; Lablanche JM Chest; 2003 Oct; 124(4):1250-8. PubMed ID: 14555553 [TBL] [Abstract][Full Text] [Related]
79. Digoxin or angiotensin converting enzyme inhibitors for congestive heart failure in geriatric patients. Which is the preferred treatment? Aronow WS Drugs Aging; 1991 Mar; 1(2):98-103. PubMed ID: 1794012 [No Abstract] [Full Text] [Related]
80. Effect of angiotensin-converting enzyme inhibitor therapy on 30-day outcome in patient > or = 65 years of age with chronic congestive heart failure. Sueta CA; Schenck A; Chowdhury M; Hall R; Simpson RJ Am J Cardiol; 2000 Nov; 86(10):1151-3, A9. PubMed ID: 11074220 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]